Sign up
Pharma Capital

LeanLife to start testing samples at Ecovatec’s manufacturing facility in British Columbia

The company intends to start sending samples of its plant-based Omega-3 products to prospective customers as well as filling existing product orders on hand
Omega fatty acid oil
Using the Ecovatec facility with its own equipment allows LeanLife to minimize overhead

LeanLife Health Inc (CSE:LLP) said Thursday that it has signed a testing agreement with the nutraceutical manufacturing company Ecovatec Solutions Inc to access its facilities for evaluating samples.

Vancouver-based LeanLife is developing Omega-3 products as oil, powder or emulsion to be used as food additives. The company has developed a patented process to isolate Omega-3 fatty acids from flax (linen) seeds.

In February, LeanLife signed a letter of intent with Ecovatec to use its manufacturing facility in Abbotsford, British Columbia.

READ: LeanLife signs letter of intent with Ecovatec for testing and production

LeanLife expects the testing at the Ecovatec facility to start within a few weeks and said it will use the opportunity to validate a “new high-volume, high-efficiency” sanitary manufacturing process.

The testing process has the potential to create new intellectual property for the company to improve its patented process to isolate Omega-3 fatty acids from flax seeds and create products.

Following a successful trial run of the new process, samples will be evaluated by an ISO 17025 accredited lab operating with a Health Canada license to ensure product quality and specifications, said the company.

DEEP DIVE: LeanLife Health rides the Omega-3 fatty acid fitness boom

“The signing of this testing agreement is another significant step forward for LeanLife Health as it moves the company closer to the commercialization of its unique plant-based Omega-3 food products,” said LeanLife Health CEO Stan Lis. “It allows for the validation and potential improvement of LeanLife’s manufacturing process in a state-of-the-art facility; and the creation of the high-quality, lab-certified samples our customers have been requesting.”

Initial production at the Ecovatec facility using equipment and technology supplied by LeanLife in a toll-processing arrangement maintains protection of LeanLife’s intellectual property.

Using the Ecovatec facility with its own equipment allows LeanLife to avoid the overhead costs and capital required to acquire its own production facility while allowing for the commercialization of its plant-based food products.

“Following a definitive agreement for contract manufacturing, LeanLife intends to begin filling existing product orders, marketing to prospective customers and generating revenues,” said Lis.

The global market for food and beverages with the Omega-3 “wonder fat” is pegged at more than $106 billion, according to data firm Statista.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 


View full LLP profile View Profile

LeanLife issues stock options

View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.